The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Cancer Therapy–Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging
Open accessAbstract
Advances in cancer therapy have resulted in significant improvement in long-term survival for many types of cancer but have also resulted in untoward side effects associated with treatment. One such complication that has become increasingly recognized is the development of cardiomyopathy and heart failure. Whether a previously healthy person from a cardiovascular perspective develops cancer therapy–related cardiac dysfunction or a high-risk cardiovascular patient requires cancer therapy, the team of oncologists and cardiologists must be better equipped with an evidence-based approach to care for these patients across the spectrum. Although the toxicities associated with various cancer therapies are well recognized, limitations to our understanding of the appropriate course of action remain. In this first of a 2-part review, we discuss the epidemiologic, pathophysiologic, risk factors, and imaging aspects of cancer therapy–related cardiac dysfunction and heart failure. In a subsequent second part, we discuss the prevention and treatment aspects, concluding with a section on evidence gap and future directions. We focus on adult patients in all stages of cancer therapy from pretreatment surveillance, to ongoing therapy, and long-term follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., Correa, C., Cutter, D., Gagliardi, G., Gigante, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209825 · Cited by 3,974 · cited 1×
“Events occurred 5 years after initial exposure and continued through the third decade following exposure.(47)”
BackgroundAdjuvant Trastuzumab in HER2-Positive Breast Cancer
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910383 · Cited by 2,775
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2014.07.012 · Cited by 1,795
Self-citationEarly Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy
Cardinale, D., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C. A., Veglia, F., Civelli, M., Lamantia, G., Colombo, N., Curigliano, G., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.013777 · Cited by 1,733
Self-citationUnderlying Causes and Long-Term Survival in Patients with Initially Unexplained Cardiomyopathy
Felker, G. M., Thompson, R. E., Hare, J. M., Hruban, R. H., Clemetson, D. E., Howard, D. L., Baughman, K. L., & Kasper, E. K. (2000) · New England Journal of Medicine · doi:10.1056/nejm200004133421502 · Cited by 1,723
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II
Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F. (1984) · Science · doi:10.1126/science.6093249 · Cited by 1,538
ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article
Cheitlin, M. D., Armstrong, W. F., Aurigemma, G. P., Beller, G. A., Bierman, F. Z., Davis, J. L., Douglas, P. S., Faxon, D. P., Gillam, L. D., Kimball, T. R., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)01065-9 · Cited by 1,402
Role of vascular endothelial growth factor in regulation of physiological angiogenesis
Ferrara, N. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.280.6.c1358 · Cited by 1,085
Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., et al. (2014) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeu192 · Cited by 1,058
Self-citationAdriamycin: A New Anticancer Drug with Significant Clinical Activity
BLUM, R. H., & CARTER, S. K. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-2-249 · Cited by 1,057
Cardinale, D., Sandri, M. T., Colombo, A., Colombo, N., Boeri, M., Lamantia, G., Civelli, M., Peccatori, F., Martinelli, G., Fiorentini, C., et al. (2004) · Circulation · doi:10.1161/01.cir.0000130926.51766.cc · Cited by 955
Self-citationAnthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Volkova, M., & Russell, R. (2012) · Current Cardiology Reviews · doi:10.2174/157340311799960645 · Cited by 872
Patnaik, J. L., Byers, T., DiGuiseppi, C., Dabelea, D., & Denberg, T. D. (2011) · Breast Cancer Research · doi:10.1186/bcr2901 · Cited by 872
Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention
Albini, A., Pennesi, G., Donatelli, F., Cammarota, R., De Flora, S., & Noonan, D. M. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp440 · Cited by 839
Sawaya, H., Sebag, I. A., Plana, J. C., Januzzi, J. L., Ky, B., Tan, T. C., Cohen, V., Banchs, J., Carver, J. R., Wiegers, S. E., et al. (2012) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.112.973321 · Cited by 814
Self-citationCarver, J. R., Shapiro, C. L., Ng, A., Jacobs, L., Schwartz, C., Virgo, K. S., Hagerty, K. L., Somerfield, M. R., & Vaughn, D. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.9777 · Cited by 793
Committee Members, Cheitlin, M. D., Armstrong, W. F., Aurigemma, G. P., Beller, G. A., Bierman, F. Z., Davis, J. L., Douglas, P. S., Faxon, D. P., Gillam, L. D., et al. (2003) · Circulation · doi:10.1161/01.cir.0000073597.57414.a9 · Cited by 745
Thavendiranathan, P., Grant, A. D., Negishi, T., Plana, J. C., Popović, Z. B., & Marwick, T. H. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.035 · Cited by 689
Type II Chemotherapy-Related Cardiac Dysfunction: Time to Recognize a New Entity
Ewer, M. S., & Lippman, S. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.827 · Cited by 646
Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation
Cardinale, D., Colombo, A., Torrisi, R., Sandri, M. T., Civelli, M., Salvatici, M., Lamantia, G., Colombo, N., Cortinovis, S., Dessanai, M. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3615 · Cited by 641
Self-citationLyu, Y. L., Kerrigan, J. E., Lin, C.-P., Azarova, A. M., Tsai, Y.-C., Ban, Y., & Liu, L. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1649 · Cited by 612
Bowles, E. J. A., Wellman, R., Feigelson, H. S., Onitilo, A. A., Freedman, A. N., Delate, T., Allen, L. A., Nekhlyudov, L., Goddard, K. A. B., Davis, R. L., et al. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs317 · Cited by 566
Ky, B., Putt, M., Sawaya, H., French, B., Januzzi, J. L., Sebag, I. A., Plana, J. C., Cohen, V., Banchs, J., Carver, J. R., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.061 · Cited by 563
Self-citationLeft ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
Cardinale, D., Sandri, M. T., Martinoni, A., Tricca LabTech, A., Civelli, M., Lamantia, G., Cinieri, S., Martinelli, G., Cipolla, C. M., & Fiorentini, C. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00748-8 · Cited by 551
Self-citationCardiovascular Disease After Hodgkin Lymphoma Treatment: 40-Year Disease Risk
van Nimwegen, F. A., Schaapveld, M., Janus, C. P. M., Krol, A. D. G., Petersen, E. J., Raemaekers, J. M. M., Kok, W. E. M., Aleman, B. M. P., & van Leeuwen, F. E. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.1180 · Cited by 514
HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
Pritchard, K. I., Shepherd, L. E., O'Malley, F. P., Andrulis, I. L., Tu, D., Bramwell, V. H., & Levine, M. N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054504 · Cited by 509
Mulvagh, S. L., Rakowski, H., Vannan, M. A., Abdelmoneim, S. S., Becher, H., Bierig, S. M., Burns, P. N., Castello, R., Coon, P. D., Hagen, M. E., et al. (2008) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2008.09.009 · Cited by 492
Cardiac side-effects of cancer chemotherapy
Monsuez, J.-J., Charniot, J.-C., Vignat, N., & Artigou, J.-Y. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.03.003 · Cited by 467
Cardiotoxicity of Anthracyclines
Cardinale, D., Iacopo, F., & Cipolla, C. M. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00026 · Cited by 463
Self-citationNegishi, K., Negishi, T., Hare, J. L., Haluska, B. A., Plana, J. C., & Marwick, T. H. (2013) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2013.02.008 · Cited by 454
Goldenberg, M. M. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88288-0 · Cited by 453
Evaluation and Management of Patients With Heart Disease and Cancer: Cardio-Oncology
Herrmann, J., Lerman, A., Sandhu, N. P., Villarraga, H. R., Mulvagh, S. L., & Kohli, M. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.05.013 · Cited by 422
Cardiac disturbances during the administration of taxol.
Rowinsky, E. K., McGuire, W. P., Guarnieri, T., Fisherman, J. S., Christian, M. C., & Donehower, R. C. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1704 · Cited by 395
Blanco, J. G., Sun, C.-L., Landier, W., Chen, L., Esparza-Duran, D., Leisenring, W., Mays, A., Friedman, D. L., Ginsberg, J. P., Hudson, M. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.8987 · Cited by 372
Lipshultz, S. E., Miller, T. L., Scully, R. E., Lipsitz, S. R., Rifai, N., Silverman, L. B., Colan, S. D., Neuberg, D. S., Dahlberg, S. E., Henkel, J. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.3404 · Cited by 323
Armstrong, G. T., Plana, J. C., Zhang, N., Srivastava, D., Green, D. M., Ness, K. K., Daniel Donovan, F., Metzger, M. L., Arevalo, A., Durand, J.-B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.3584 · Cited by 321
Silber, J. H., Cnaan, A., Clark, B. J., Paridon, S. M., Chin, A. J., Rychik, J., Hogarty, A. N., Cohen, M. I., Barber, G., Rutkowski, M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.022 · Cited by 299
Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab
Choueiri, T. K., Mayer, E. L., Je, Y., Rosenberg, J. E., Nguyen, P. L., Azzi, G. R., Bellmunt, J., Burstein, H. J., & Schutz, F. A. B. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.9129 · Cited by 293
Ezaz, G., Long, J. B., Gross, C. P., & Chen, J. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000472 · Cited by 276
Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality
Pavo, N., Raderer, M., Hülsmann, M., Neuhold, S., Adlbrecht, C., Strunk, G., Goliasch, G., Gisslinger, H., Steger, G. G., Hejna, M., et al. (2015) · Heart · doi:10.1136/heartjnl-2015-307848 · Cited by 269
Cancer Therapy–Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies
Hahn, V. S., Lenihan, D. J., & Ky, B. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000665 · Cited by 264
Self-citationJenkins, C., Moir, S., Chan, J., Rakhit, D., Haluska, B., & Marwick, T. H. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn484 · Cited by 253
Field, J. J., Kanakkanthara, A., & Miller, J. H. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.02.035 · Cited by 251
Vejpongsa, P., & Yeh, E. T. H. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.201 · Cited by 225
Left Ventricular Mass in Patients With a Cardiomyopathy After Treatment With Anthracyclines
Neilan, T. G., Coelho-Filho, O. R., Pena-Herrera, D., Shah, R. V., Jerosch-Herold, M., Francis, S. A., Moslehi, J., & Kwong, R. Y. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.07.040 · Cited by 224
TASSANMANGINA, S., CODOREAN, D., METIVIER, M., COSTA, B., HIMBERLIN, C., JOUANNAUD, C., BLAISE, A., ELAERTS, J., & NAZEYROLLAS, P. (2006) · European Journal of Echocardiography · doi:10.1016/j.euje.2005.04.009 · Cited by 213
Hall, P. S., Harshman, L. C., Srinivas, S., & Witteles, R. M. (2013) · JACC: Heart Failure · doi:10.1016/j.jchf.2012.09.001 · Cited by 207
5-fluorouracil induced cardiotoxicity: Review of the literature
Sorrentino, M. F., Kim, J., Foderaro, A. E., & Truesdell, A. G. (2012) · Cardiology Journal · doi:10.5603/cj.2012.0084 · Cited by 196
Richards, C. J., Je, Y., Schutz, F. A. B., Heng, D. Y. C., Dallabrida, S. M., Moslehi, J. J., & Choueiri, T. K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4309 · Cited by 180
Putt, M., Hahn, V. S., Januzzi, J. L., Sawaya, H., Sebag, I. A., Plana, J. C., Picard, M. H., Carver, J. R., Halpern, E. F., Kuter, I., et al. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2015.241232 · Cited by 178
Self-citationMason, J. W., Bristow, M. R., Billingham, M. E., & Daniels, J. R. (1978) · PubMed · Cited by 175
Dodos, F., Halbsguth, T., Erdmann, E., & Hoppe, U. C. (2008) · Clinical Research in Cardiology · doi:10.1007/s00392-007-0633-6 · Cited by 174
Pein, F., Sakiroglu, O., Dahan, M., Lebidois, J., Merlet, P., Shamsaldin, A., Villain, E., de Vathaire, F., Sidi, D., & Hartmann, O. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601904 · Cited by 171
Hybrid PET/MR Imaging of the Heart: Potential, Initial Experiences, and Future Prospects
Rischpler, C., Nekolla, S. G., Dregely, I., & Schwaiger, M. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.105353 · Cited by 167
Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review
Curigliano, G., Mayer, E. L., Burstein, H. J., Winer, E. P., & Goldhirsch, A. (2010) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2010.05.006 · Cited by 166
Thavendiranathan, P., Wintersperger, B. J., Flamm, S. D., & Marwick, T. H. (2013) · Circulation: Cardiovascular Imaging · doi:10.1161/circimaging.113.000899 · Cited by 163
Fallah‐Rad, N., Lytwyn, M., Fang, T., Kirkpatrick, I. D., & Jassal, D. S. (2008) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-10-5 · Cited by 152
High-Dose Ifosfamide Is Associated with Severe, Reversible Cardiac Dysfunction
Quezado, Z., Wilson, W. H., Cunnion, R. E., Parker, M. M., Reda, D., Bryant, G., & Ognibene, F. P. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-1-199301010-00006 · Cited by 144
Morris, P. G., Chen, C. C. L., Steingart, R. M., Fleisher, M., Lin, N., Moy, B., Come, S. E., Sugarman, S. M., Abbruzzi, A., Lehman, R. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1359 · Cited by 143
PET and MR Imaging: The Odd Couple or a Match Made in Heaven?
Catana, C., Guimarães, A. R., & Rosen, B. R. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.112771 · Cited by 139
Onitilo, A. A., Engel, J. M., Stankowski, R. V., Liang, H., Berg, R. L., & Doi, S. A. R. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2039-z · Cited by 133
Sandri, M. T., Cardinale, D. M., Zorzino, L., Passerini, R., Lentati, P., Martinoni, A., Martinelli, G., & Cipolla, C. M. (2003) · Clinical Chemistry · doi:10.1373/49.2.248 · Cited by 123
Self-citationSkovgaard, D. C., Hasbak, P., & Kjær, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096736 · Cited by 108
Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs
Jiji, R. S., Kramer, C. M., & Salerno, M. (2012) · Journal of Nuclear Cardiology · doi:10.1007/s12350-012-9512-2 · Cited by 101
Strategies to Prevent and Treat Cardiovascular Risk in Cancer Patients
Cardinale, D. M., Bacchiani, G., Beggiato, M., Colombo, A., & Cipolla, C. M. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.01.008 · Cited by 97
Self-citationKrop, I. E., Suter, T. M., Dang, C. T., Dirix, L. Y., Romieu, G., Zamagni, C., Citron, M. L., Campone, M., Xu, N., Smitt, M. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.7782 · Cited by 93
Mavinkurve‐Groothuis, A. M. C., Loonen, J. J., Bellersen, L., Pourier, M. S., Feuth, T. B., Bökkerink, J. P. M., Hoogerbrugge, P. M., & Kapusta, L. (2009) · Pediatric Blood & Cancer · doi:10.1002/pbc.21913 · Cited by 87
Radiation-Induced Heart Disease
Filopei, J., & Frishman, W. H. (2012) · Cardiology in Review · doi:10.1097/crd.0b013e3182431c23 · Cited by 84
Dranitsaris, G., Rayson, D., Vincent, M. D., Chang, J., Gelmon, K. A., Sandor, D. W., & Reardon, G. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9803-5 · Cited by 82
Stoodley, P. W., Richards, D. A., Boyd, A. C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.046 · Cited by 72
Torsion analysis in the early detection of anthracycline-mediated cardiomyopathy
Motoki, H., Koyama, J., Nakazawa, H., Aizawa, K., Kasai, H., Izawa, A., Tomita, T., Miyashita, Y., Kumazaki, S., Takahashi, M., et al. (2011) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ejechocard/jer172 · Cited by 68
Giordano, S. H., Booser, D. J., Murray, J. L., Ibrahim, N. K., Rahman, Z. U., Valero, V., Theriault, R. L., Rosales, M., Rivera, E., Frye, D. K., et al. (2002) · PubMed · Cited by 65
Noninvasive Imaging of Cardiovascular Injury Related to the Treatment of Cancer
Kongbundansuk, S., & Hundley, W. G. (2014) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2014.06.007 · Cited by 64
Cardiac risk in the treatment of breast cancer: assessment and management
Valachis, A., & Nilsson, C. (2015) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s47227 · Cited by 62
Yang, B., & Papoian, T. (2012) · Journal of Applied Toxicology · doi:10.1002/jat.2813 · Cited by 57
Valachis, A., Nearchou, A. D., Lind, P., & Mauri, D. N. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2189-z · Cited by 51
Oreto, L., Todaro, M. C., Umland, M. M., Kramer, C. M., Qamar, R., Carerj, S., Khandheria, B. K., & Paterick, T. E. (2012) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2012.09.001 · Cited by 49
Éderhy, S., Massard, C., Dufaître, G., Balheda, R., Meuleman, C., Gomez‐Roca, C., Izzedine, H., Cohen, A. A., & Soria, J. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9546-8 · Cited by 41
Groarke, J. D., Choueiri, T. K., Slosky, D., Cheng, S. C., & Moslehi, J. J. (2014) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-014-0335-0 · Cited by 41
State of the Art in Cardiac Hybrid Technology: PET/MR
Nappi, C., & Fakhri, G. E. (2013) · Current Cardiovascular Imaging Reports · doi:10.1007/s12410-013-9213-5 · Cited by 31
Cited by
Global burden of heart failure: a comprehensive and updated review of epidemiology
Savarese, G., Becher, P. M., Lund, L. H., Seferovic, P., Rosano, G. M. C., & Coats, A. J. S. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvac013 · Cited by 3,315
Global epidemiology of heart failure
Khan, M. S., Shahid, I., Bennis, A., Rakisheva, A., Metra, M., & Butler, J. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01046-6 · Cited by 540
Self-citationCarvedilol for Prevention of Chemotherapy-Related Cardiotoxicity
Avila, M. S., Ayub-Ferreira, S. M., de Barros Wanderley, M. R., das Dores Cruz, F., Gonçalves Brandão, S. M., Rigaud, V. O. C., Higuchi-dos-Santos, M. H., Hajjar, L. A., Kalil Filho, R., Hoff, P. M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.049 · Cited by 507
Cardiotoxicity of Anthracyclines
Cardinale, D., Iacopo, F., & Cipolla, C. M. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00026 · Cited by 463
Self-citationZhao, L., Qi, Y., Xu, L., Tao, X., Han, X., Yin, L., & Peng, J. (2018) · Redox Biology · doi:10.1016/j.redox.2017.12.013 · Cited by 344
Metadata
- Authors
- Bloom, M. W., Hamo, C. E., Cardinale, D., Ky, B., Nohria, A., Baer, L., Skopicki, H., Lenihan, D. J., Gheorghiade, M., Lyon, A. R., & Butler, J.
- Venue
- Circulation: Heart Failure
- Published
- 2016-01
- Volume
- 9
- Issue
- 1
- Pages
- e002661-e002661
- ISSN
- 1941-3289 (ISSN-L)
- 1941-3297
- OpenAlex
- W3014286838
- Cited by
- 334
- References
- 86
- FWCI
- 23.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.